Antibiotic · Beta-lactam · Cephalosporin
Cefepime (Maxipime)
Also called Maxipime
Indications
- Moderate to severe pneumonia, including Pseudomonas (label)
- Empiric therapy for febrile neutropenia, 2 g every 8 h (label)
- Complicated intra-abdominal infection, with metronidazole (label)
- Urinary tract and uncomplicated skin infections (label)
- Empiric gram-negative and Pseudomonas coverage in sepsis and hospital-acquired pneumonia; post-neurosurgical meningitis (off-label)
Dosing
| Where | Dose |
|---|---|
| Antimicrobials | Cefepime: Reduce at CrCl 60 or less; neurotoxicity (confusion, myoclonus, nonconvulsive seizures) in AKI |
On the quick cards
Mechanism of action
Cefepime is a fourth-generation cephalosporin that binds penicillin-binding proteins and blocks cell-wall synthesis (label), so dividing bacteria lyse; killing depends on time above the MIC. Its positively charged N-methylpyrrolidinium group makes it a zwitterion that crosses gram-negative porins quickly and binds chromosomal AmpC beta-lactamases poorly, keeping it active against many AmpC producers. ESBLs and carbapenemases hydrolyze it. In the brain, beta-lactams antagonize GABA-A receptors, the likely basis of its neurotoxicity.
Pharmacology
- Infectious: gram-negative rods including Pseudomonas, plus MSSA and streptococci; no activity against MRSA, enterococci or Bacteroides, hence metronidazole for abdominal infection
- CNS: encephalopathy, myoclonus, seizures and nonconvulsive status epilepticus, mostly with unadjusted doses in renal impairment (label); fewer delirium- and coma-free days than piperacillin-tazobactam (11.9 vs 12.2 of 14; ACORN 2023)
- Renal: stage 3 AKI 7.0% vs 7.5% with piperacillin-tazobactam (ACORN 2023)
- Hematologic: positive Coombs test without hemolysis 16.2%; falling prothrombin activity (label)
- Skin and local: rash 1.1%, phlebitis 1.3% (label)
Pharmacokinetics
| Half-life | About 2 h (label) |
|---|---|
| Distribution | Vd about 18 L at steady state (label) |
| Protein binding | About 20% (label) |
| Metabolism | Minor: under 1% of the dose appears in urine as N-methylpyrrolidine (label) |
| Elimination | About 85% unchanged in urine (label) |
| Renal dosing | Adjust at CrCl 60 mL/min or less (label) |
| Dialysis | A 3-h session removes about 68%; 1 g on day 1, then 500 mg daily for most infections (label) |
| Infusion | Over about 30 min (label); extended infusion off-label |
Chemistry
- Cephalosporin, C₁₉H₂₄N₆O₅S₂ for the cefepime moiety (label), with an aminothiazolyl methoxyimino side chain at C-7 and a quaternary N-methylpyrrolidinium at C-3
- Supplied as cefepime hydrochloride mixed with L-arginine, which sets the reconstituted pH at 4–6 (label)
Adverse effects and cautions
In the one-pagers
In the algorithms
Other antibiotic drugs
Sources
- FDA label: Cefepime for Injection (Hospira, 2024)
- Qian 2023 (ACORN trial)
For education and exam preparation only. Follow your institution’s protocols. Typical adult values for study. Follow the order, the label and your institution's protocols.